VYNE Therapeutics (VYNE) Projected to Post Quarterly Earnings on Thursday

VYNE Therapeutics (NASDAQ:VYNE) is projected to announce its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $0.14 million for the quarter.

VYNE Therapeutics Price Performance

VYNE stock opened at $2.55 on Thursday. The company has a fifty day moving average price of $2.83 and a two-hundred day moving average price of $2.48. VYNE Therapeutics has a one year low of $1.57 and a one year high of $4.30. The stock has a market cap of $37.62 million, a price-to-earnings ratio of -2.97 and a beta of 1.28.

Analysts Set New Price Targets

A number of equities analysts have commented on VYNE shares. BTIG Research started coverage on shares of VYNE Therapeutics in a research report on Monday, November 18th. They set a “buy” rating and a $8.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $5.75 price objective on shares of VYNE Therapeutics in a research report on Wednesday, February 19th.

Insider Activity

In other VYNE Therapeutics news, Director Patrick G. Lepore bought 15,000 shares of VYNE Therapeutics stock in a transaction dated Wednesday, January 15th. The stock was bought at an average price of $2.92 per share, with a total value of $43,800.00. Following the completion of the transaction, the director now owns 51,472 shares in the company, valued at $150,298.24. The trade was a 41.13 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.80% of the stock is currently owned by company insiders.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.